Kyverna's Q2 2026 Update: RMAT Designation for miv-cel in Progressive MS and BLA on Track for Q4

summarizeSummary

Kyverna reported Q2 2026 financials with $199.4M cash and runway into 2028, announced FDA RMAT designation for miv-cel in progressive MS, and confirmed its rolling BLA for stiff person syndrome is on track for Q4 2026 completion.

check_boxKey Events · Earnings and Guidance · KYTX

• RMAT Designation for miv-cel in Progressive MS

  The FDA granted Regenerative Medicine Advanced Therapy designation for miv-cel in non-active secondary progressive multiple sclerosis based on compelling clinical data, enabling increased FDA engagement and eligibility for priority and rolling reviews.

• Rolling BLA for SPS on Track for Q4 2026

  Kyverna initiated its rolling BLA for stiff person syndrome, submitted the CMC module, and expects to complete the submission in Q4 2026, with potential priority review and commercial launch in 2027.

• Cash Runway Extended into 2028

  Cash, cash equivalents, and marketable securities totaled $199.4 million as of June 30, 2026, which together with available loan facility draws is expected to fund operations into 2028.

• Q2 2026 Net Loss Narrows to $38.3M

  Net loss was $38.3 million ($0.63 per share) compared to $42.1 million ($0.97 per share) in Q2 2025, driven by lower R&D expenses as the SPS registrational trial completed enrollment.

auto_awesomeAnalysis · KYTX · Life Sciences

Kyverna's Q2 update delivers multiple catalysts. The FDA granted RMAT designation for miv-cel in non-active secondary progressive MS, a new indication with significant unmet need. Meanwhile, the rolling BLA for stiff person syndrome remains on track for Q4 2026 completion, with potential priority review and commercial launch in 2027. Cash of $199.4M provides runway into 2028, reducing near-term financing risk. The net loss narrowed year-over-year, and upcoming data readouts in Q3 2026—including KYSA-8 SPS 12-month and gMG Phase 2 follow-up—could further de-risk the pipeline.